Countervail Corporation


US Parent Patent awarded for use of galantamine as Method of Treating Organophosphorus Poisoning.

In February 2011, Countervail was successful in obtaining approval from the USPTO for the parent patent associated with the licensed galantamine technology targeted for the development of medical countermeasures to poisoning from organophosphorus compounds such as nerve agents and pesticides. Additional commercially viable claims are also being pursued under a Continuation-In-Part (CIP).